Method Article

Antimicrobial resistance patterns and their encoding genes among clinical isolates of *Acinetobacter baumannii* in Ahvaz, Southwest Iran

Mojtaba Moosavian\(^a, b\), Khadijeh Ahmadi\(^a\), Saeed Shoja\(^c\), Jalal Mardaneh\(^d\), Fatemeh Shahi\(^a\), Maryam Afzali\(^a, *\)

\(^a\) Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
\(^b\) Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
\(^c\) Infectious and Tropical Disease Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
\(^d\) Department of Microbiology, School of Medicine, and Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran

**ABSTRACT**

*Acinetobacter baumannii* is one of the most important organisms in nosocomial infections. Antibiotic resistance in this bacterium causes many problems in treating patients. This study aimed to investigate antibiotic resistance patterns and resistance-related genes in clinical isolates of *Acinetobacter baumannii*. This descriptive study was conducted on 124 isolates of *Acinetobacter baumannii* collected from clinical samples in two teaching hospitals in Ahvaz. The antibiotic resistance pattern was determined by disk diffusion. The presence of genes coding for antibiotic resistance was determined using the polymerase chain reaction method. Out of 124 isolates, the highest rate of resistance was observed for rifampin (96.8%). The resistance rate for imipenem, meropenem, colistin, and polymyxin-B were 78.2%, 73.4%, 0.8% and 0.8%, respectively. The distribution of *qnrA*, *qnrB*, *qnrS*, Tet A, TetB, and *Sul1* genes were 52.6%, 0%, 3.2%, 93.5% 69.2%, and 6.42%, respectively. High prevalence of TetA, TetB, and *qnrA* genes among *Acinetobacter baumannii* isolated strains in this study indicate the important role of these genes in multidrug resistance in this bacteria.

- *Acinetobacter baumannii* is an important human pathogen that has attracted the attention of many researchers Antibiotic resistance in this bacterium causes many problems in treating patients.
- The resistance rate for imipenem, meropenem, colistin, and polymyxin-B were 78.2%, 73.4%, 0.8% and 0.8%, respectively. The distribution of *qnrA*, *qnrB*, *qnrS*, Tet A, TetB, and *Sul1* genes were 52.6%, 0%, 3.2%, 93.5% 69.2%, and 6.42%, respectively.

© 2020 Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

* Corresponding author.
E-mail address: afzalmaryam7753@gmail.com (M. Afzali).

https://doi.org/10.1016/j.mex.2020.101031
2215-0161/© 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

Bacterial nosocomial infections cause many problems in the treatment and mortality of patients, due to their antibiotic resistance. Among these bacteria, *Acinetobacter baumannii* is an important human pathogen that has attracted the attention of many researchers [1]. *A. baumannii* also causes various diseases such as septicemia, ventilator-associated pneumonia, meningitis, urinary tract infections, endocarditis and wound infections [2]. The amount of colonization of *A.baumannii* is increasing in hospitalized patients, especially in patients who have been hospitalized for a long time or have received broad-spectrum antibiotics or anticancer drugs [3]. Today, the spread of antibiotic resistance genes by creating multiple drug resistance (MDR) has become an important problem in the treatment of Acinetobacter infection [4]. Different previous studies have shown that *A. baumannii* is resistant to the majority of antibiotics including fluoroquinolones, cephalosporins, carbapenems, tetracycline, and aminoglycosides [5]. Antimicrobial resistance of *A.baumannii* is mediated by acquired and inherent mechanisms, which include enzymatic changes, a mutation in the target genes, changes in the permeability of the outer membrane, and increased expression of the efflux pumps [6]. Pumping mediation out of the bacteria, due to the mechanisms of the efflux, is one of the reasons for MDR. There are several types of Tet genes encoding the efflux pump, which causes resistance to tetracycline and among them, tetA and tetB genes are the most common [7].

Quinolones are a bunch of antimicrobial compounds that are commonly used to treat infections caused by *A. baumannii*. Several mechanisms make these bacteria resistant to fluoroquinolones. One of these mechanisms is the presence of the qnr gene. The plasmid-mediated quinolone resistance (PMQR) genes, such as qnrA, qnrB, and qnrS, are responsible for quinolone resistance in *A. baumannii* isolates [8,9]. These qnr genes encode proteins of the pentapeptide repeat family that protects DNA from quinolone by binding to DNA gyrase and topoisomerase IV and causes resistance to quinolones [10,11]. Since *A. baumannii* infections have caused severe complications of treatment for hospitalized patients in Iran and other countries, information on the prevalence of antibiotic resistance genes and the pattern of resistance of these infections is very important. There are not any data available to describe the prevalence of qnrA, qnrB, qnrS genes of *A. baumannii* in Ahvaz, southwest Iran, therefore, our study aimed to investigate antibiotic resistance pattern and resistance-related genes such as qnrA, qnrB, qnrS, Tet A, TetB, and Sul1, in clinical isolates of *A. baumannii* isolated from patients admitted into diverse wards of Golestan and Imam Khomeini hospital in Ahvaz by PCR.

Subjects and methods

Isolation and characterization of bacteria

In this descriptive cross-sectional study, 124 non-duplicate *A. baumannii* isolates were collected from various infections of patients admitted into diverse wards of Golestan and Imam Khomeini
Table 1
The sequence of primers used in the study.

| Primers  | Primer sequence (5’-3’) | Product size (bp) | Annealing Temp (°C) | Reference |
|----------|-------------------------|------------------|---------------------|-----------|
| TetA     | F-GCT ACA TCC TGC TTG CCT TC | 210              | 55                  | 19        |
|          | R-CAT AGA TCG CCG TGA AGA CG |                  |                     |           |
| TetB     | F-AGTC GCT GGA GGC AAG TTG TG | 659              | 55                  | 19        |
|          | R-GTA ATG GGC CA A TAA CAC CG |                  |                     |           |
| qnrA     | F-ATCGTTGAGGCAAGTTTGAAGCA  | 516              | 53                  | 20        |
|          | R-GATCGCCAAGGCGAGAGTTTGG   |                  |                     |           |
| qnrB     | F-GATCGTGAAGCAGCAAGGTTG    | 469              | 53                  | 20        |
|          | R-AGATGCGTTGATGTTGTTCC     |                  |                     |           |
| qnrS     | F-ACGACATCACTGCAACTGCAA    | 417              | 53                  | 20        |
|          | R-TAAATTCCGACCTGATACGG     |                  |                     |           |
| sulI     | F-GCGGCTGGTTCACGTGAACG     | 432              | 55                  | 21        |
|          | R-GCCGATCGGGCTGAAGTCCGG    |                  |                     |           |
| bлаOXA-51- like | F- T-GATGTCGACTTCATCTTGG | 353              | 57                  | 18        |

hospital in Ahvaz, Iran, from July 2011 to January 2013. 124 strains of A. baumannii were obtained from different clinical specimens, including tracheal aspirate, cerebrospinal fluid, wound, urine, discharge, blood, pleura, catheter, and eye infections. At first, A. baumannii isolates were identified using standard biochemical and microbiological tests such as OF, IMVIC, TSI, SIM, MRVP, and catalase. A. baumannii isolates were saved in Tryptic Soy Broth (TSB) (Merck, Germany), containing glycerol (30%) at -70°C [12].

Antibiotic susceptibility testing

The determination of antibiotic susceptibility was tested by the Kirby-Bauer disk diffusion method based on the Clinical and Laboratory Standard Institute (CLSI, 2016) guidelines [13].

The antibiotics tested in this study included tetracycline (30 μg), meropenem (10 μg), amikacin (30 μg), imipenem (10 μg), ceftiraxone (30 μg), piperacillin/tazobactam (100/10 μg), colistin sulfate (10 μg), piperacillin (100 μg), ceftazidime (30 μg), ciprofloxacin (5 μg), cefepime (30 μg), cotrimoxazole (25 μg), aztreonam (30 μg), ampicillin-sulbactam (10/10 μg), tigecycline (15 μg), rifampin (5 μg), tobramycin (10 mg), polymyxin B (300 U), and gentamicin (10 μg) (MAST, Group Ltd, Merseyside, UK).

To conduct the test, a suspension of bacterial colonies equivalent to 0.5 McFarland standard was prepared and plated on Muller-Hinton agar medium (Merck, Germany). Then, the media were incubated for 18-24 hours at 37°C. The results were reported according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI, 2016) [13]. A. baumannii ATCC 19606 was used as the positive control strain [14]. The US Food and Drug Administration-approved criteria for Enterobacteriaceae used for tigecycline stop point, respectively [15,16].

DNA extraction

DNA extraction of A. baumannii was performed by the boiling method [17].

PCR amplification of tetracycline, sulfonamide, and quinolone resistance genes

The specific primers (Table 1) for the study was confirmed by BLAST, and Sul1 (sulfonamide resistance), qnrA, qnrB, qnrS (quinolone resistance), tetA and tetB (tetracycline resistance) genes (Bioneer Korea) were detected by PCR.

Detection of blaOXA-51-like

To confirm the identity of A. baumannii, blaOXA-51-like gene was examined by PCR using specific primers listed in Table 1 [18]. To amplify this gene, each reaction was carried out in a final volume of
25 μl containing 10 μl Mastermix (Ampliqon, Denmark), 0.5 μl of each primer (10 pM), 5 μl DNA template. The amplification reaction was programmed by thermal cycler (Eppendorf, Germany) as follows: Initial denaturation at 94°C for 3 min; 35 cycles of 94°C for 45 s, annealing 72°C for 1min and final extension 72°C for 5 min. The PCR products were separated on 1.5% agarose gel containing ethidium bromide and finally visualized in the gel documentation system. A. baumannii NCTC 12156 (ATCC 19606) was used as a positive control [18].

**PCR amplification of Tet genes**

The sequences of primers used for the detection of tetA and tetB are shown in Table 1. The reaction volume was set to 25 μl containing 10 μl Mastermix (Ampliqon, Denmark), 1 μl Primer forward (10 pM), 1 μl Primer reverse (10 pM), 5 μl DNA template. Amplification of DNA was performed in a thermal cycler (Eppendorf, Germany) with 5 min of initial denaturation at 95°C, followed by 35 cycles, including denaturation at 95°C for 30 s, annealing at 55°C for 1 min, extension at 72°C for 1 min, and a final extension at 72°C for 10 min [19]. The PCR products were electrophoresed on 1.5% agarose gel containing ethidium bromide and finally visualized in the gel documentation system. Shigella sonnei ATCC 9290 was used as a positive control strain.

**PCR for the screening of qnr and sul1 genes**

The specific primers of Sul1, qnrA, qnrB, qnrS are shown in Table 1. PCR amplification was performed using 10 μl Mastermix (Ampliqon, Denmark), 0.5 μl from each reverse and forward primers (10 pM), 5 μl DNA template. The final volume for each reaction was 25 μL. The amplification reaction was carried out by thermal cycler (Eppendorf, Germany) with an initial denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 45 s, annealing for 45 s at primer set specific temperatures in Table 1, and extension at 72°C for 1 min, followed by a final extension at 72°C for 10 min [20,21]. PCR products were electrophoresed on ethidium bromide containing 1.5% of agarose gel and finally visualized in the gel documentation system.

The confirmed Klebsiella pneumoniae strain containing the qnr gene was used as a positive control for qnr genes and E. coli DH5α was used as a positive control for the sul1 gene. Also, the strain of Escherichia coli ATCC25922 was used as a negative control strain in this study.

**Statistical analysis**

The results were analyzed using SPSS version 16 to obtain frequencies and comparisons among clones. A nonparametric chi-square test was used. A P value < 0.05 was considered statistically significant.

**Results**

124 A. baumannii isolates were collected. The rate of isolates from each ward and specimen are shown in Table 2. As shown in Table 2, of 124 isolates of A. baumannii isolated from the type of clinical specimens, the highest infection was related to the Tracheal aspirate with 57.3% and the lowest level of infection was related to eye infection with 0.8%.

**Antimicrobial susceptibility test**

Antibiotic susceptibility test results by the disk diffusion method are shown in Table 3. Among 124 isolates, one isolate (0.8%) was resistant to colistin and 123 isolates (98.2%) were susceptible to this antibiotic.
had other reported such infection (74.2%).

**Table 2**
The rate of *Acinetobacter baumannii* species isolated from each ward and specimen.

| Ward                  | Rate of isolates | Specimen               | Rate of isolates |
|-----------------------|------------------|------------------------|------------------|
| ICU                   | 74.2             | Tracheal aspirate      | 57.3             |
| Outpatients           | 8.1              | Cerebrospinal fluid    | 11.3             |
| Neurosurgery          | 4                | Wound                  | 10.5             |
| Dermatology           | 4                | Urine                  | 8.1              |
| Orthopaedic           | 2.4              | Blood                  | 3.2              |
| Gynecology and Obstetrics | 2.4         | Pleura                 | 1.6              |
| Surgery               | 0.8              | Catheter               | 1.6              |
| Neonatal              | 0.8              | Eye infection          | 0.8              |

**Table 3**
The results of antibiogram test for *A.baumannii* isolates.

| Antibiotic            | Sensitive | Intermediate | Resistant |
|-----------------------|-----------|--------------|----------|
| Imipenem              | 24.2      | 1.6          | 74.2     |
| Meropenem             | 19.4      | 0.8          | 79.8     |
| Ceftazidime           | 15.3      | 2.4          | 82.3     |
| Cefepime              | 16.1      | 4            | 79.8     |
| Ceftriaxone           | 1.6       | 12.1         | 86.3     |
| Colistin              | 98.2      | 0            | 0.8      |
| Piperacillin          | 12.1      | 3.2          | 84.7     |
| Piperacillin-tazobactam | 16.9     | 1.6          | 81.5     |
| Polymyxin-B           | 99.2      | 0            | 0.8      |
| Gentamicin            | 28.2      | 4.8          | 66.9     |
| Tobramycin            | 33.9      | 1.6          | 64.5     |
| Amikacin              | 21        | 12.1         | 66.9     |
| Tetracycline          | 21.8      | 12.1         | 66.1     |
| Ampicillin-sulbactam  | 32.3      | 21.8         | 46       |
| Ciprofloxacin         | 13.7      | 1.6          | 84.7     |
| Cotrimoxazole         | 19.4      | 4.8          | 75.8     |
| Rifampin              | 0         | 3.2          | 96.8     |
| Aztreonam             | 0         | 4.8          | 95.2     |
| Tigecycline (FDA)     | 6.5       | 58.1         | 35.5     |
| Tigecycline (Jones)   | 45.2      | 50.8         | 4        |

**Determination of frequency of antibiotic-resistant genes**

The percentage of *qnrA, qnrB,* and *qnrS* genes in *A. baumannii* strains were (52.6%), (0%), and (3.2%), respectively. According to PCR results, in the isolates of *A. baumannii, TetA* and *TetB* genes were detected in 93.5% and 69.2% of strains, respectively. PCR results showed that 6.42% of *A. baumannii* species were carried *sul1* gene.

**Discussion**

Various studies have shown that *A. baumannii* strains are resistant to most antibiotics, and these multi-drug-resistant strains are rapidly expanding among hospitalized patients [4]. These resistances are often mediated by genes that are located on moving genetic elements such as transposons and integrons and are simply distributed among bacteria [22]. In our study, most isolates of *A. baumannii* (74.2%) were isolated from patients in ICU. Other studies worldwide have shown that the rate of infection with *A. baumannii* in ICU patients is high [23,24]. Also, *A. baumannii* can cause infections such as ventilator-associated pneumonia (VAP), particularly in ICU patients. Previously, it has been reported that *A. baumannii* is more common in tracheal aspirate specimens [25,26]. In comparison with other studies, most of the *A. baumannii* isolates (57.3%) were obtained from tracheal aspirates.

In the present research, antimicrobial susceptibility pattern showed that polymyxin-B and colistin had the most effect on *A. baumannii* isolates. Colistin is the latest antibiotic for the treatment of multi-
drug resistant A. baumannii infections [27,28]. However, colistin-resistant isolates have been reported worldwide. In this study, only 0.8% of the isolates were resistant to this antimicrobial agent. Fallah et al. (2014) reported that the prevalence of the A. baumannii strains to colistin was (1.8%) [29].

The results of this study, according to other studies, showed an increase in resistance to antibiotics β-lactam, ciprofloxacin, cotrimoxazole, Piperacillin, and tetracycline by more than 50%. The results of this research consistent with the previous reports [30-32].

The level of resistance of A. baumannii isolates to ciprofloxacin is important because the clinical application of ciprofloxacin is better than carbapenems [33]. One of the main goals of this study was to determine the distribution of antibiotic resistance genes. The tetA and tetB genes encoding the efflux pump, and they are factors of resistance to tetracycline and minocycline. There was a significant relationship between the presence of these genes, tetA (93.5%) and tetB (69.2%), and tetracycline resistance in this study. In a study conducted by Asadollahi et al, the prevalence of tetA and tetB genes, (95.5%) and (65%) was reported [34]. These results were consistent with our findings. But, our results were higher than the Previous study in Ahvaz [30]. Increasing the frequency of tetA and tetB genes in this research had shown that resistance to A. baumannii is increasing, due to the increasing use of tetracycline.

PMQR genes are responsible for resistance to quinolone in A. baumannii. The prevalence of quinolone resistance in A. baumannii has increased in recent years and has complicated the treatment of these infections [35]. The qnrA appears predominant qnr gene identified in our study. The prevalence of qnrB gene was an agreement with the study carried out by Mirnejad et al [36]. The prevalence of qnrS gene in our study was similar to another study in Tehran [37]. Also, due to the excessive consumption of quinolones and fluoroquinolones, the emergence of resistant strains has caused many problems in treating and creating a transferable resistance among bacteria.

In recent years, the use of sulfonamide and trimethoprim for the treatment of infections is increasing in most countries, and excessive use of these drugs has led to resistance and unsuccessful treatment [38]. In this study, we showed that 6.42% of A. baumannii isolates had the sul1 gene. Our results are not consistent with previous studies [30,39,40]. The most reason for this contrast with other studies may be due to differences in clinical specimens, the number of samples, sampling method, type of study, geographical area, and the availability of various antibiotics.

This study showed that the most effective antibiotic against clinical strains of A. baumannii was colistin and we recommend clinicians to use this agent in patients infected with MDR A. baumannii. The results of this study indicated that tet A, tet B, and qnrA genes are the most important resistant factors to tetracycline and ciprofloxacin in A. baumannii isolates in our region. Due to the high prevalence of these genes, physicians should be careful in prescribing fluoroquinolones and tetracyclines antibiotics in the treatment of infections associated with this bacterium.

Limitations

In this study, the results had certain limitations. The major limitations were the short period of our study, sample size, and not examining more genes of antibiotic resistance.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgments

This work was a part of PhD thesis, which was granted (No.90126) and financially supported by deputy vice-chancellor for research affairs of Ahvaz Jundishapur Uni-versity of Medical Sciences, and infectious and tropical dis-eases research center.

References

[1] LT. Curtis, Prevention of hospital-acquired infections: review of non-pharmacological interventions, J. Hosp. Infect. 69 (2008) 204–219.
Clinical overview, Antimicrob. and Infect. Dis. 59 (6) (2007) 1210–1215.

A Robicsek, GA Jacoby, DC Hooper, The worldwide emergence of plasmid-mediated quinolone resistance, Lancet 6 (2006) 629–640.

M. Mulvey, A Simor, Antimicrobial resistance in hospitals: How concerned should we be, CMAJ 180 (2009) 408–415.

C. Xiang, P. Weijsuan, Z. Weiqiu, P. Zhiming, G Song, J. Xian, Quinolone resistance in Escherichia coli and Salmonella spp. isolates from diseased chickens during 1993–2008 in China, AJMR 5 (19) (2011) 3078–3083.

V. Kees, A. Essene-Zandbergen, Arie Kant, Dik Mevis, Characterization of qnr-positive Escherichia coli isolates from food-producing animals in the Netherlands, JAC 67 (2011) 239–240.

H. Goudarzi, M. Douraghi, Z. Chalavand, M. Goudarzi, Assessment of antibiotic resistance pattern in Acinetobacter baumannii carrying bla oxA type genes isolated from hospitalized patients, Nov. Biomed. 1 (2) (2013) 54–61.

Clinical and Laboratory Standards Institute, 2016. Performance Standards for Antimicrobial Susceptibility Testing: 21st Informational Supplement. CLSI document M100-S21. CLSI, Wayne, PA.

H. Oh, Clinical and Laboratory Standards Institute, Performance standards for antimicrobial disk susceptibility testing; 20th informational supplement, CLSI/NCCLS M100-S20. Clinical and Laboratory Standards Institute, Wayne, 2010.

RN Jones, MJ Ferraro, LB Reiler, PC Schreckenberger, JM Swenson, HS Sader, Multicenter studies of tigecycline disk diffusion susceptibility result for Acinetobacter spp., J. Clin. Microbiol. 45 (1) (2007) 227–231.

W. Pharmacuetics, Tygacil (tigecycline) for Injection [package insert], Wyeth Pharmaceuticals Inc, Philadelphia, 2005.

TS Andriamananena, E. Ratsima, HC Kolanirina, F. Randriamiriana, L. Ramparany, JF Carod, V. Richard, A. Antoine Talarmin, Dissemination of multidrug-resistant Acinetobacter baumannii in various hospitals of antananarivo madagascar, Ann. Clin. Microbiol. Antimicrob. 9 (2010) 17.

S. Shoja, M. Moosavian, A. Peymani, MA Tabatabaiefar, S. Rostami, N. Ebrahimi, Genotyping of carbapenem-resistant Acinetobacter baumannii isolated from tracheal tube discharge of hospitalized patients in intensive care units, Alhaz, Iran, Iran. J. Microbiol. 5 (4) (2012) 315–322.

HC Su, GC Ying, R. Tao, RO Zhang, LR Fogarty, DW Kolpin, The occurrence of antibiotic resistance and characterization of resistance genes and integrons in Enterobacteriaceae isolated from integrated fish farms in south China, J. Environ. Monit. 13 (2011) 3229–3236.

A. Robicsek, J. Strahilevitz, DF Sahm, GA Jacoby, DC Hooper, qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States, AAC 50 (2006) 2872–2874.

H. Arabi, I. Pakzad, A. Nasrollahi, H. Hosainzadegan, F. Azizi Jalilian, M. Taherikalani, N. Samadi, and MonadiSefidan A. Lactamase (ESBL) and Non-ESBL Producing Escherichia coli isolated from iranian hospitals, JJM 8 (7) (2015) e19961.

H. Jin, XM Xu, Zh. Mu, Z. Gao, and P. Liu, Drug-resistant gene-based genotyping for Acinetobacter baumannii in tracing epidemicological events and for clinical treatment within nosocomial settings, Chin. Med. J. 122 (3) (2009) 301–316.

C. Fontana, M. Favaro, S. Minelli, MC Bossa, GP Testore, F. Leonardis, N. Silvia, C. Favalli, Acinetobacter baumannii in intensive care unit: a novel system to study the clonal relationship among the isolates, BMC Infect. Dis. 8 (2008) 79.

M. Kempf, JM. Rolain, The emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options, Int. J. Antimicrob. Agents 39 (2) (2012) 105–114.

L Dijkstra, A. Nemec, H. Seiffert, An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii, Nat. Rev. Microbiol. 5 (12) (2007) 959–951.

A. Peymani, S. Farajnia, MR Naehai, N. Sohrabi, L. Abbasi, K. Ansarin, F. Azhari, Prevalence of class 1 integron among multidrug-resistant Acinetobacter baumannii in Tabriz, northwest of Iran, Pol. J. Microbiol. 61 (1) (2012) 57–60.

T Pacheco, RH Bustos, D Gonzalez, V. Garzón, J.C García, D. Ramirez, An Approach to Measuring Colistin Plasma Levels Regarding the Treatment of Multidrug-Resistant Bacterial Infection, Antibiotics (2019) 1–19.

Y. Cai, D. Chai, R. Wang, B. Liang, N. Bai, Colistin resistance in Acinetobacter baumannii in Europe: clinical reports, mechanisms, and antimicrobial strategies, J. Antimicrob. Chemother. 67 (7) (2012) 1607–1615.

F. Fallah, M. Noori, A. Hashemi, H. Goudarzi, A. Karimi, S. Erfanianmesh, et al., Prevalence of bla NDM, bla PER, bla VEB, bla IMP, and bla VIM Genes among Acinetobacter baumannii isolated from Two Hospitals of Tehran, Iran, Scientifica (Cairo 2014 (2014) 245162.

S. Kiani, H. Mottaz, A. Serajian, E. Tajbakht, Detection of integrons in acinetobacter baumannii strains isolated from the nosocomial infections of Ahvaz City and their relation with the resistance pattern, JMJLR 3 (1) (2016) 50–63.

G. Baran, A. Erbay, H. Bodur, P. Onguru, E. Akinci, N. Balaban, MA Cevik, Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections, Int. J. Infect. Dis. 12 (1) (2008) 16–21.

Z Hashemizadeh, A. Bazargani, A. Emami, MJ Rahimi, Acinetobacter baumannii antibiotic resistance and frequency of ESBL-producing strain in ICU patient of Namazi Hospital, JQUMS 4 (2) (2010) 47–53.

EN. Lagamay, Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asia countries, Am. J. Infect. Control 36 (4) (2008) 8–10.

P. Asadollahi, M. Akbari, S. Soroush, M. Taherikalani, K. Asadollahi, Antimicrobial resistance patterns and their encoding genes among Acinetobacter baumannii strains isolated from burned patients, Burns 38 (8) (2012) 1198–1203.

H Wang, JL Dzink-Fox, M. Chen, SB Levy, Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli Strains from China: Role of R mutations, AAC 45 (5) (2001) 1515–1521.
[36] Mirnejad R, Heidary M, Bahramian A, Goudarzi M and Pournajaf A. Evaluation of Polymyxin B Susceptibility Profile and Detection of Drug Resistance Genes among Acinetobacter Baumannii Clinical Isolates in Tehran, Iran during 2015-2016. Mediterr. J. Hematol. Infect. Dis. 2018; 10: e2018044.

[37] H Khayat, N SadeghiFard, I Pakzad, L Azimi, S Delfani, K Sayehmiri, S Soroush, L Bogdanovic, M Taherikalani, Determination of different fluoroquinolone mechanisms among clinical isolates of Acinetobacter baumannii in Tehran, Iran, Iran. Red Crescent Med. J. 26 (2017) e58798.

[38] A Larochelle, D Lovatsis, J.E. Walter, W Easton, SA Farrell, Recurrent Urinary tract infection, J. Obstet. Gynaecol. Can. 32 (2010) 1082–1101.

[39] B Soltani, H Heidari, H Sedigh Ebrahim-Saraie, N Hadi, J Mardaneh, M Motamedifar, Molecular characteristics of multiple and extensive drug-resistant Acinetobacter baumannii isolates obtained from hospitalized patients in Southwestern Iran. Le Infezioni in Medicine, Infez. Med. 26 (1) (2018) 67–76 1.

[40] H Razavi Nikoo, A Ardebili, J Mardaneh, Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter Baumannii Isolates in Iran: An Update, Microb. Drug Resist. 23 (6) (2017) 744–756.